Clinical trials: Macular Telangiectasia Type 2
Macular Telangiectasia Type 2
A Study to Determine the Safety and Efficacy of NT-501 With MHFM
This study is to determine the long-term levels of CNTF, and the clinical safety and efficacy of the NT-501 implants with the Medica Hollow Fiber Membrane (MHFM) in participants with macular telangiectasia type 2.
- Trial name
- NCT06397131
- Testing
- NT-501 CNTF Implant
- Where
- 6 sites in United States, Australia
- Volunteers
- 12 people
- Sponsor
- Neurotech Pharmaceuticals
Macular Telangiectasia Type 2 (MacTel)
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants…
- Trial name
- NCT06971939
- Testing
- NT-501/revakinagene taroretcel-lwey
- Where
- 26 sites in United States, Australia
- Volunteers
- 234 people
- Sponsor
- Neurotech Pharmaceuticals
Macular Telangiectasia Type 2
Serine and Fenofibrate Study in Patients With MacTel Type 2
This is a Phase 2a study of the effect of serine supplementation and fenofibrate treatment on serum deoxysphingolipid levels in patients with macular telangiectasia type 2 (MacTel). This study involves six arms.
- Trial name
- SAFE (NCT04907084)
- Testing
- Serine, Fenofibrate
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 89 people
- Sponsor
- The Lowy Medical Research Institute Limited
Macular Telangiectasia Type 2 (MacTel)
Study of Serine Supplementation to Protect Vision in MacTel
The goal of this clinical trial is to look at the efficacy and safety of giving oral serine (an amino acid) on the progression of structural and functional changes of the retina in people with MacTel type 2.
- Trial name
- SEErine (NCT07342439)
- Testing
- L-serine
- Where
- 12 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- The Lowy Medical Research Institute Limited
MacTel (Macular Telangiectasia) Type 2
Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)
This was a prospective, multicenter, single-masked, sham-controlled extension study designed to provide long-term safety and efficacy follow-up data for subjects with MacTel who had NT-501 implanted intraocularly and/or underwent…
- Trial name
- NCT03071965
- Testing
- Ciliary neurotrophic factor (CNTF), Surgery
- Where
- 11 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Neurotech Pharmaceuticals
Macular Telangiectasia Type 2
Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2
This is a multi-center, open-label, 6-month study to evaluate the safety of bilateral CNTF implants in participants with Macular Telangiectasia Type 2.
- Trial name
- NCT04729972
- Testing
- NT-501 CNTF implant
- Where
- 10 sites in United States, Australia
- Volunteers
- 33 people
- Sponsor
- Neurotech Pharmaceuticals
Macular Telangiectasia Type 2 (MacTel)
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A
This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.
- Trial name
- NCT03316300
- Testing
- NT-501
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- Neurotech Pharmaceuticals
Macular Telangiectasia Type 2
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B
This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.
- Trial name
- NCT03319849
- Testing
- NT-501
- Where
- 27 sites in United States, Australia and 1 more
- Volunteers
- 119 people
- Sponsor
- Neurotech Pharmaceuticals
Macular Telangiectasia Type 2
A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel
This study is a phase 2, randomized, multi-center, single-masked study to evaluate the efficacy and safety of the NT-501 implants in participants with Mactel.
- Trial name
- NCT01949324
- Testing
- Ciliary neurotrophic factor (CNTF), NT-501 Implant, NT-501 Implant procedure
- Where
- 11 sites in United States, Australia
- Volunteers
- 67 people
- Sponsor
- Neurotech Pharmaceuticals
Type 2 Idiopathic Macular Telangiectasia
Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)
The purpose of this study is to investigate if a new drug called ranibizumab is effective to treat a rare bilateral disease of the macula: type 2 idiopathic macular telangiectasia (type 2 IMT).
- Trial name
- NCT00504400
- Testing
- Intravitreal injection ranibizumab
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital, Bonn